カテゴリ： LP Information, 世界, 医療/バイオ

癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の世界市場2025-2031：モノクローナル抗体、ポリクローナル抗体

■ 英語タイトル：Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Growth 2025-2031
	■ 発行会社/調査会社：LP Information ■ 商品コード：LP22DC4939 ■ 発行日：2025年2月 ■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ■ 産業分野：医薬品 ■ ページ数：113 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後2-3営業日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥527,040	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥790,560	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,054,080	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の世界市場2025-2031：モノクローナル抗体、ポリクローナル抗体]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体のグローバル市場規模は、2024年のxxx百万ドルから2031年までにxxx百万ドルに増加すると推定されており、2024年～2031年の年平均成長率（CAGR）はxx%を示しています。貿易戦争とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対する貿易戦争の直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体のアジア太平洋市場は、2024年にxxx百万ドルの市場規模が見込まれ、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の米国市場は、2024年にxxx百万ドルの規模があり、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体のヨーロッパ市場は、2024年にxxx百万ドルの規模が見込まれ、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の中国市場は、2024年にxxx百万ドルの規模があり、2024年～2031年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要な癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体関連企業としては、Sino Biological, Inc.、 LifeSpan BioSciences, Inc、 Abcam、 Thermo Fisher Scientific (China) Co., Ltd.、 Bio-Techne、 Boster Biological Technology、 Merck、 RayBiotech, Inc.、 Assay Genie、 Creative Biolabs、 MyBiosource, Inc.、 OriGene Technologies, Inc.、 Creative Diagnostics、 Abbexa、 Biorbyt、 Abeomics Inc.、 CUSABIO、 Enzo Life Sciences, Inc.などをカバーしています。売上の面では世界最大の2社が2024年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながら癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリューチェーン分析などのミクロの詳細にまで及びます。当レポートは読者が貿易戦争およびロシア・ウクライナ戦争中に世界中で癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2024年で、市場の予測は2024年～2031年までのものです。

*** 市場セグメンテーション ***

この調査では癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場を細分化し、種類別 (モノクローナル抗体、ポリクローナル抗体)、用途別 (フローサイトメトリー、ELISA、ウエスタンブロット、免疫沈降、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：モノクローナル抗体、ポリクローナル抗体

・用途別区分：フローサイトメトリー、ELISA、ウエスタンブロット、免疫沈降、その他

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の範囲、調査方法など
第2章：エグゼクティブサマリー、世界の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2020年～2024年までの推移データ、および2031年までの市場予測
第3章：企業別癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の年間販売量2020-2031、地域別現状・将来分析
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別セグメント：モノクローナル抗体、ポリクローナル抗体
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別販売量：2020-2024年の販売量、売上、市場シェア、販売価格
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別セグメント：フローサイトメトリー、ELISA、ウエスタンブロット、免疫沈降、その他
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別販売量：2020-2024年の販売量、売上、市場シェア、販売価格

企業別世界の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場
・企業別のグローバル癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場データ：2022-2024年の年間販売量、市場シェア
・企業別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の年間売上：2022-2024年の売上、市場シェア
・企業別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売価格
・主要企業の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の地域別レビュー
・地域別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場規模2020-2024：年間販売量、売上
・主要国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場規模2020-2024：年間販売量、売上
・アメリカ州の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売の成長
・アジア太平洋の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売の成長
・ヨーロッパの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売の成長
・中東・アフリカの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売の成長

アメリカ州市場
・アメリカ州の国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売量、売上（2020-2024）
・アメリカ州の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別販売量
・アメリカ州の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売量、売上（2020-2024）
・アジア太平洋の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別販売量
・アジア太平洋の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売量、売上（2020-2024）
・ヨーロッパの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別販売量
・ヨーロッパの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売量、売上（2020-2024）
・中東・アフリカの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別販売量
・中東・アフリカの癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の製造コスト構造分析
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の製造プロセス分析
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の主要なグローバル販売業者
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の主要なグローバル顧客

地域別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場予測レビュー
・地域別の癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体市場規模予測（2025-2031）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の種類別市場規模予測
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の用途別市場規模予測

主要企業分析
Sino Biological, Inc.、 LifeSpan BioSciences, Inc、 Abcam、 Thermo Fisher Scientific (China) Co., Ltd.、 Bio-Techne、 Boster Biological Technology、 Merck、 RayBiotech, Inc.、 Assay Genie、 Creative Biolabs、 MyBiosource, Inc.、 OriGene Technologies, Inc.、 Creative Diagnostics、 Abbexa、 Biorbyt、 Abeomics Inc.、 CUSABIO、 Enzo Life Sciences, Inc.
・企業情報
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体製品
・癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体販売量、売上、価格、粗利益（2022-2024）
・主要ビジネス概要
・最新動向

調査の結果

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody is an unconjugated antibody to CEACAM5 (CD66e).
The global market for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody is estimated to increase from US$ million in 2024 to reach US$ million by 2031, exhibiting a CAGR of % during 2025-2031. Keeping in mind the uncertainties of Trade War and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of trade war on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The United States Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
The China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market is expected at value of US$ million in 2024 and grow at approximately % CAGR during 2024 and 2031.
Global key Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody players cover Sino Biological, Inc., LifeSpan BioSciences, Inc, Abcam, Thermo Fisher Scientific (China) Co., Ltd. and Bio-Techne, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2024.

[Report Coverage]
This latest report provides a deep insight into the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market, with both quantitative and qualitative data, to help readers understand how the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market scenario changed across the globe during trade war and Russia-Ukraine War.
The base year considered for analyses is 2024, while the market estimates and forecasts are given from 2025 to 2031. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market and forecasts the market size by Type (Monoclonal Antibody and Polyclonal Antibody,), by Application (Flow Cytometry, ELISA, Western Blot and Immunoprecipitation), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Monoclonal Antibody
Polyclonal Antibody
Segmentation by application
Flow Cytometry
ELISA
Western Blot
Immunoprecipitation
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Sino Biological, Inc.
LifeSpan BioSciences, Inc
Abcam
Thermo Fisher Scientific (China) Co., Ltd.
Bio-Techne
Boster Biological Technology
Merck
RayBiotech, Inc.
Assay Genie
Creative Biolabs
MyBiosource, Inc.
OriGene Technologies, Inc.
Creative Diagnostics
Abbexa
Biorbyt
Abeomics Inc.
CUSABIO
Enzo Life Sciences, Inc.

[Chapter Introduction]
Chapter 1: Scope of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Research Methodology, etc.
Chapter 2: Executive Summary, global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size (sales and revenue) and CAGR, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size by region, by type, by application, historical data from 2020 to 2025, and forecast to 2031.
Chapter 3: Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody sales, revenue, average price, global market share, and industry ranking by company, 2020-2024
Chapter 4: Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sino Biological, Inc., LifeSpan BioSciences, Inc, Abcam, Thermo Fisher Scientific (China) Co., Ltd., Bio-Techne, Boster Biological Technology, Merck, RayBiotech, Inc. and Assay Genie, etc.
Chapter 14: Research Findings and Conclusion

*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region, 2020, 2025 & 2031
2.1.3 World Current & Future Analysis for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country/Region, 2020, 2025 & 2031
2.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Polyclonal Antibody
2.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
2.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
2.3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue and Market Share by Type (2020-2024)
2.3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Type (2020-2024)
2.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Application
2.4.1 Flow Cytometry
2.4.2 ELISA
2.4.3 Western Blot
2.4.4 Immunoprecipitation
2.4.5 Other
2.5 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
2.5.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Market Share by Application (2020-2024)
2.5.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue and Market Share by Application (2020-2024)
2.5.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Application (2020-2024)
3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Company
3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Breakdown Data by Company
3.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Company (2022-2024)
3.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Company (2022-2024)
3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Company (2022-2024)
3.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Company (2022-2024)
3.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Company (2022-2024)
3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Company
3.4 Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Location Distribution
3.4.2 Players Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region
4.1 World Historic Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Geographic Region (2020-2024)
4.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Geographic Region (2020-2024)
4.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Geographic Region
4.2 World Historic Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country/Region (2020-2024)
4.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Country/Region (2020-2024)
4.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Country/Region
4.3 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.4 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.5 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.6 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
5 Americas
5.1 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country
5.1.1 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024)
5.1.2 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024)
5.2 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
5.3 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region
6.1.1 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2020-2024)
6.1.2 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2020-2024)
6.2 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
6.3 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country
7.1.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024)
7.1.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024)
7.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
7.3 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country
8.1.1 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024)
8.1.2 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024)
8.2 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
8.3 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
10.3 Manufacturing Process Analysis of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
10.4 Industry Chain Structure of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors
11.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customer
12 World Forecast Review for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region
12.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Forecast by Region
12.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Region (2025-2031)
12.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue Forecast by Region (2025-2031)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Type
12.7 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Application
13 Key Players Analysis
13.1 Sino Biological, Inc.
13.1.1 Sino Biological, Inc. Company Information
13.1.2 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.1.3 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.1.4 Sino Biological, Inc. Main Business Overview
13.1.5 Sino Biological, Inc. Latest Developments
13.2 LifeSpan BioSciences, Inc
13.2.1 LifeSpan BioSciences, Inc Company Information
13.2.2 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.2.3 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.2.4 LifeSpan BioSciences, Inc Main Business Overview
13.2.5 LifeSpan BioSciences, Inc Latest Developments
13.3 Abcam
13.3.1 Abcam Company Information
13.3.2 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.3.3 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.3.4 Abcam Main Business Overview
13.3.5 Abcam Latest Developments
13.4 Thermo Fisher Scientific (China) Co., Ltd.
13.4.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
13.4.2 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.4.3 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.4.4 Thermo Fisher Scientific (China) Co., Ltd. Main Business Overview
13.4.5 Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
13.5 Bio-Techne
13.5.1 Bio-Techne Company Information
13.5.2 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.5.3 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.5.4 Bio-Techne Main Business Overview
13.5.5 Bio-Techne Latest Developments
13.6 Boster Biological Technology
13.6.1 Boster Biological Technology Company Information
13.6.2 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.6.3 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.6.4 Boster Biological Technology Main Business Overview
13.6.5 Boster Biological Technology Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.7.3 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 RayBiotech, Inc.
13.8.1 RayBiotech, Inc. Company Information
13.8.2 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.8.3 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.8.4 RayBiotech, Inc. Main Business Overview
13.8.5 RayBiotech, Inc. Latest Developments
13.9 Assay Genie
13.9.1 Assay Genie Company Information
13.9.2 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.9.3 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.9.4 Assay Genie Main Business Overview
13.9.5 Assay Genie Latest Developments
13.10 Creative Biolabs
13.10.1 Creative Biolabs Company Information
13.10.2 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.10.3 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.10.4 Creative Biolabs Main Business Overview
13.10.5 Creative Biolabs Latest Developments
13.11 MyBiosource, Inc.
13.11.1 MyBiosource, Inc. Company Information
13.11.2 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.11.3 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.11.4 MyBiosource, Inc. Main Business Overview
13.11.5 MyBiosource, Inc. Latest Developments
13.12 OriGene Technologies, Inc.
13.12.1 OriGene Technologies, Inc. Company Information
13.12.2 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.12.3 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.12.4 OriGene Technologies, Inc. Main Business Overview
13.12.5 OriGene Technologies, Inc. Latest Developments
13.13 Creative Diagnostics
13.13.1 Creative Diagnostics Company Information
13.13.2 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.13.3 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.13.4 Creative Diagnostics Main Business Overview
13.13.5 Creative Diagnostics Latest Developments
13.14 Abbexa
13.14.1 Abbexa Company Information
13.14.2 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.14.3 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.14.4 Abbexa Main Business Overview
13.14.5 Abbexa Latest Developments
13.15 Biorbyt
13.15.1 Biorbyt Company Information
13.15.2 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.15.3 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.15.4 Biorbyt Main Business Overview
13.15.5 Biorbyt Latest Developments
13.16 Abeomics Inc.
13.16.1 Abeomics Inc. Company Information
13.16.2 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.16.3 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.16.4 Abeomics Inc. Main Business Overview
13.16.5 Abeomics Inc. Latest Developments
13.17 CUSABIO
13.17.1 CUSABIO Company Information
13.17.2 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.17.3 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.17.4 CUSABIO Main Business Overview
13.17.5 CUSABIO Latest Developments
13.18 Enzo Life Sciences, Inc.
13.18.1 Enzo Life Sciences, Inc. Company Information
13.18.2 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
13.18.3 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2022-2024)
13.18.4 Enzo Life Sciences, Inc. Main Business Overview
13.18.5 Enzo Life Sciences, Inc. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales CAGR by Geographic Region (2020, 2025 & 2031) & ($ millions)
Table 2. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales CAGR by Country/Region (2020, 2025 & 2031) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Polyclonal Antibody
Table 5. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2024) & (K Units)
Table 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
Table 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2020-2024) & ($ million)
Table 8. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2020-2024)
Table 9. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Type (2020-2024) & (US$/Unit)
Table 10. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2024) & (K Units)
Table 11. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Table 12. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2020-2024)
Table 13. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2020-2024)
Table 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Application (2020-2024) & (US$/Unit)
Table 15. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Company (2022-2024) & (K Units)
Table 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Company (2022-2024)
Table 17. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Company (2022-2024) ($ Millions)
Table 18. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Company (2022-2024)
Table 19. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Company (2022-2024) & (US$/Unit)
Table 20. Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Producing Area Distribution and Sales Area
Table 21. Players Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Products Offered
Table 22. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Geographic Region (2020-2024) & (K Units)
Table 26. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share Geographic Region (2020-2024)
Table 27. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Geographic Region (2020-2024) & ($ millions)
Table 28. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Geographic Region (2020-2024)
Table 29. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country/Region (2020-2024) & (K Units)
Table 30. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country/Region (2020-2024)
Table 31. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country/Region (2020-2024) & ($ millions)
Table 32. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country/Region (2020-2024)
Table 33. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024) & (K Units)
Table 34. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2020-2024)
Table 35. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024) & ($ Millions)
Table 36. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2020-2024)
Table 37. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2024) & (K Units)
Table 38. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
Table 39. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2024) & (K Units)
Table 40. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Table 41. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2020-2024) & (K Units)
Table 42. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2020-2024)
Table 43. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2020-2024) & ($ Millions)
Table 44. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2020-2024)
Table 45. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2024) & (K Units)
Table 46. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
Table 47. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2024) & (K Units)
Table 48. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Table 49. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024) & (K Units)
Table 50. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2020-2024)
Table 51. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024) & ($ Millions)
Table 52. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2020-2024)
Table 53. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2024) & (K Units)
Table 54. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
Table 55. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2024) & (K Units)
Table 56. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Table 57. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2024) & (K Units)
Table 58. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2020-2024)
Table 59. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2024) & ($ Millions)
Table 60. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2020-2024)
Table 61. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2024) & (K Units)
Table 62. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2020-2024)
Table 63. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2024) & (K Units)
Table 64. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Table 65. Key Market Drivers & Growth Opportunities of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
Table 66. Key Market Challenges & Risks of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
Table 67. Key Industry Trends of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
Table 68. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors List
Table 71. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customer List
Table 72. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Region (2025-2031) & (K Units)
Table 73. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Forecast by Region
Table 74. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Region (2025-2031) & ($ millions)
Table 75. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share Forecast by Region (2025-2031)
Table 76. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Country (2025-2031) & (K Units)
Table 77. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Country (2025-2031) & ($ millions)
Table 78. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Region (2025-2031) & (K Units)
Table 79. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Region (2025-2031) & ($ millions)
Table 80. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Country (2025-2031) & (K Units)
Table 81. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Country (2025-2031) & ($ millions)
Table 82. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Country (2025-2031) & (K Units)
Table 83. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Country (2025-2031) & ($ millions)
Table 84. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Type (2025-2031) & (K Units)
Table 85. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share Forecast by Type (2025-2031)
Table 86. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Type (2025-2031) & ($ Millions)
Table 87. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share Forecast by Type (2025-2031)
Table 88. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Forecast by Application (2025-2031) & (K Units)
Table 89. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share Forecast by Application (2025-2031)
Table 90. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Forecast by Application (2025-2031) & ($ Millions)
Table 91. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share Forecast by Application (2025-2031)
Table 92. Sino Biological, Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 93. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 94. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 95. Sino Biological, Inc. Main Business
Table 96. Sino Biological, Inc. Latest Developments
Table 97. LifeSpan BioSciences, Inc Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 98. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 99. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 100. LifeSpan BioSciences, Inc Main Business
Table 101. LifeSpan BioSciences, Inc Latest Developments
Table 102. Abcam Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 103. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 104. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 105. Abcam Main Business
Table 106. Abcam Latest Developments
Table 107. Thermo Fisher Scientific (China) Co., Ltd. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 108. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 109. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 110. Thermo Fisher Scientific (China) Co., Ltd. Main Business
Table 111. Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
Table 112. Bio-Techne Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 113. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 114. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 115. Bio-Techne Main Business
Table 116. Bio-Techne Latest Developments
Table 117. Boster Biological Technology Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 118. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 119. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 120. Boster Biological Technology Main Business
Table 121. Boster Biological Technology Latest Developments
Table 122. Merck Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 123. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 124. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 125. Merck Main Business
Table 126. Merck Latest Developments
Table 127. RayBiotech, Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 128. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 129. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 130. RayBiotech, Inc. Main Business
Table 131. RayBiotech, Inc. Latest Developments
Table 132. Assay Genie Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 133. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 134. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 135. Assay Genie Main Business
Table 136. Assay Genie Latest Developments
Table 137. Creative Biolabs Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 138. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 139. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 140. Creative Biolabs Main Business
Table 141. Creative Biolabs Latest Developments
Table 142. MyBiosource, Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 143. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 144. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 145. MyBiosource, Inc. Main Business
Table 146. MyBiosource, Inc. Latest Developments
Table 147. OriGene Technologies, Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 148. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 149. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 150. OriGene Technologies, Inc. Main Business
Table 151. OriGene Technologies, Inc. Latest Developments
Table 152. Creative Diagnostics Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 153. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 154. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 155. Creative Diagnostics Main Business
Table 156. Creative Diagnostics Latest Developments
Table 157. Abbexa Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 158. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 159. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 160. Abbexa Main Business
Table 161. Abbexa Latest Developments
Table 162. Biorbyt Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 163. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 164. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 165. Biorbyt Main Business
Table 166. Biorbyt Latest Developments
Table 167. Abeomics Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 168. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 169. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 170. Abeomics Inc. Main Business
Table 171. Abeomics Inc. Latest Developments
Table 172. CUSABIO Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 173. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 174. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 175. CUSABIO Main Business
Table 176. CUSABIO Latest Developments
Table 177. Enzo Life Sciences, Inc. Basic Information, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 178. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Offered
Table 179. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2022-2024)
Table 180. Enzo Life Sciences, Inc. Main Business
Table 181. Enzo Life Sciences, Inc. Latest Developments
List of Figures
Figure 1. Picture of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
Figure 2. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate 2020-2031 ($ Millions)
Figure 8. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2024 & 2031) & ($ millions)
Figure 9. Product Picture of Monoclonal Antibody
Figure 10. Product Picture of Polyclonal Antibody
Figure 11. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type in 2024
Figure 12. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2020-2024)
Figure 13. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Consumed in Flow Cytometry
Figure 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market: Flow Cytometry (2020-2024) & (K Units)
Figure 15. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Consumed in ELISA
Figure 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market: ELISA (2020-2024) & (K Units)
Figure 17. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Consumed in Western Blot
Figure 18. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market: Western Blot (2020-2024) & (K Units)
Figure 19. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Consumed in Immunoprecipitation
Figure 20. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market: Immunoprecipitation (2020-2024) & (K Units)
Figure 21. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Consumed in Other
Figure 22. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market: Other (2020-2024) & (K Units)
Figure 23. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2020-2024)
Figure 24. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application in 2024
Figure 25. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market by Company in 2024 ($ Million)
Figure 26. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Company in 2024
Figure 27. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Geographic Region (2020-2024)
Figure 28. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Geographic Region in 2024
Figure 29. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2020-2024)
Figure 30. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country/Region in 2024
Figure 31. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2020-2024 (K Units)
Figure 32. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2020-2024 ($ Millions)
Figure 33. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2020-2024 (K Units)
Figure 34. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2020-2024 ($ Millions)
Figure 35. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2020-2024 (K Units)
Figure 36. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2020-2024 ($ Millions)
Figure 37. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2020-2024 (K Units)
Figure 38. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2020-2024 ($ Millions)
Figure 39. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country in 2024
Figure 40. Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country in 2024
Figure 41. United States Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 42. Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 43. Mexico Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 44. Brazil Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 45. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region in 2024
Figure 46. APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Regions in 2024
Figure 47. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 48. Japan Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 49. South Korea Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 50. Southeast Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 51. India Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 52. Australia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 53. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country in 2024
Figure 54. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country in 2024
Figure 55. Germany Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 56. France Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 57. UK Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 58. Italy Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 59. Russia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth 2020-2024 ($ Millions)
Figure 60. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country in 2024_x0

※参考情報

癌胎児性抗原関連細胞接着分子5（CEACAM5）抗体は、がんの診断や治療において重要な役割を果たす分子です。本稿では、CEACAM5抗体の概念、特徴、種類、用途、関連技術などについて詳しく解説いたします。

CEACAM5は、体内の多くの細胞に発現する細胞接着分子であり、特に大腸がんにおけるマーカーとして知られています。CEACAM5はもともと胎児において発現している抗原であり、成人においては腫瘍細胞に特異的に発現することが多いため、腫瘍マーカーとしての機能を持ちます。このため、CEACAM5はがんの早期発見や治療のモニタリングにおいて重要な指標となっています。

CEACAM5抗体は、主にがん細胞に特異的に結合することで、がんの診断や治療のために利用されます。これらの抗体は、免疫系の一部であるB細胞によって生成され、特定の抗原に対して特異的に反応します。CEACAM5に対する抗体は、がん細胞の表面に発現するCEACAM5に結合し、がん細胞の認識と排除を助ける役割を果たします。

CEACAM5抗体は、いくつかの異なる種類に分類されます。まず、モノクローナル抗体と多クローン抗体の二つがあります。モノクローナル抗体は、一種のB細胞から生成された単一の抗体であり、特異性が高いという特徴があります。これに対し、多クローン抗体は、複数のB細胞から生成された抗体の混合物であり、特定の抗原に対する幅広い反応性を示します。CEACAM5に対して開発されたモノクローナル抗体は、その高い特異性から診断用途での利用が期待されており、一方で多クローン抗体は、研究のための目的に利用されることが一般的です。

CEACAM5抗体の用途は多岐にわたります。主な用途の一つは、がんの早期診断におけるバイオマーカーとしての利用です。CEACAM5は、特に大腸がんや膵臓がん、肺がんなどの腫瘍において高い発現を示すため、これらのがんの早期発見や経過観察に役立ちます。また、CEACAM5の血中濃度を測定することによって、がんの治療効果や再発の有無を評価することも可能です。

さらに、CEACAM5抗体は治療法の開発にも応用されています。特に、抗CEACAM5抗体を用いた抗体療法が検討されており、がん細胞を標的とする治療法の一つとして期待されています。抗体を用いたがん治療は、特異性が高いため、正常細胞への影響を減少させ、治療の副作用を軽減することが可能です。これにより、患者の生活の質を向上させることが期待されています。

CEACAM5抗体の関連技術として、ELISA（酵素結合免疫吸着法）や西方ブロット法、フローサイトメトリーなどの技術があります。これらの技術は、CEACAM5抗体の特異性や親和性を評価するために使用されます。ELISAは、血中のCEACAM5濃度を定量的に測定するための一般的な方法であり、臨床検査でも広く用いられています。西方ブロット法は、CEACAM5抗体の特異的な結合を確認するために用いられる技術であり、抗体の特異性や感度を評価するのに役立ちます。また、フローサイトメトリーは、細胞表面におけるCEACAM5の発現を定量化するために用いられ、特定の細胞集団に対する抗体の結合能力を評価するのに役立ちます。

近年、CEACAM5抗体に関する研究は進展しており、新たな抗体治療法や診断法の開発が期待されています。また、CEACAM5の発現が異なるがん種における役割についての研究も進行中であり、これによりがんの個別化医療の実現に寄与することが期待されています。

CEACAM5抗体は、がんの診断・治療における極めて重要なツールであり、今後の研究や臨床応用においてますます注目されることでしょう。私たちの理解が深まることで、新たな治療法が生まれ、多くの患者さんの命を救う可能性が広がることが期待されます。CEACAM5に関連する研究が進展することで、未来のがん治療がより効果的で安全なものとなることを願っています。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

癌胎児性抗原関連細胞接着分子5 （CEACAM5）抗体の世界市場2025-2031：モノクローナル抗体、ポリクローナル抗体

グローバル市場調査会社